scispace - formally typeset
S

Susan E. Campbell

Researcher at Brown University

Publications -  26
Citations -  671

Susan E. Campbell is an academic researcher from Brown University. The author has contributed to research in topics: Internal medicine & Progeria. The author has an hindex of 10, co-authored 20 publications receiving 529 citations. Previous affiliations of Susan E. Campbell include University of Utah.

Papers
More filters
Journal ArticleDOI

Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome

TL;DR: This study provides a robust untreated disease survival profile that can be used for comparisons now and in the future to assess changes in survival with treatments for Hutchinson-Gilford progeria syndrome.
Journal ArticleDOI

Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome

TL;DR: Among patients with HGPS, lonafarnib monotherapy, compared with no treatment, was associated with a lower mortality rate after 2.2 years of follow-up, and the association of monotherapy using the protein farnesyltransferase inhibitor lonfarnib with mortality rate was evaluated.
Journal ArticleDOI

Disease Progression in Hutchinson-Gilford Progeria Syndrome: Impact on Growth and Development

TL;DR: The analysis shows evidence of a newly identified abnormal growth pattern for children with Hutchinson-Gilford progeria syndrome, and skeletal and dental findings are suggestive of a developmental dysplasia rather than a classical aging process.
Journal ArticleDOI

Imaging Characteristics of Cerebrovascular Arteriopathy and Stroke in Hutchinson-Gilford Progeria Syndrome

TL;DR: A unique intracranial and superior cervical arteriopathy in HGPS distinct from other vasculopathies of childhood, such as Moyamoya, and cerebrovascular disease of aging, including atherosclerosis is reported.
Journal ArticleDOI

Family history of breast cancer. Impact on the disease experience.

TL;DR: The results suggest that women with F HOBC have a different disease experience than those without an affected relative, and healthcare providers should be aware that compliance with mammography and therapy guidelines may vary with FHOBC.